Want to be part of the next wave of innovation in immunology? We’re #hiring and eager to meet you at our networking event during #ACG2022.Connect with our recruiters to learn more today, or view our current open positions here: bit.ly/3wfHucg

Bucks Happening Announces Happening Women bit.ly/3SdBOc6 #Business

Our JNJInnovative Medicine Immunology team attended this year’s #UEGWeek congress virtually and in-person to showcase our work in #Gastroenterology! Take a look at our virtual newsroom to learn more: bit.ly/3BXzoGh #MyCompany

At 9 weeks pregnant, Bethany learned her blood type was incompatible with her baby’s and was diagnosed with #HDFN. Despite losing her child, she became her own advocate and now helps other women through Allo Hope Foundation: bit.ly/3f211Ix #PregnancyAndInfantLossAwarenessMonth

Approximately 240 million people worldwide suffer from #autoantibody diseases, many without effective treatment options. Driven by this unmet patient need we are focused on advancing our understanding of these diseases. Learn more with Katie AZ: bit.ly/3gXvrMw

[Thread 1/4] Inflammatory bowel disease (#IBD) cases – which include Crohn’s disease and ulcerative colitis – increased by 85 percent globally from 1990 to 2017. #CCAwarenessWeek

In an article for Nature Portfolio, Janssen’s David M. Lee, M.D., Ph.D., and Navin Rao, Ph.D., discuss the promise of new therapeutic strategies driven by scientific advancement around #Tcell function. Learn more: bit.ly/3B8CQ2X

Janssen is pleased to participate in the ASH Annual Meeting, where we’re presenting new data from our investigative therapy for #Autoantibody diseases like warm autoimmune hemolytic anemia (wAIHA). Learn more about our work: bit.ly/3W5sYyT #ASH22

👏🏻

Innovators at #JNJ are aiming to help improve maternal health outcomes by studying rare diseases like #HDFN. For #MaternalHealth Awareness Day, learn about the passion these innovators have for their work and the progress J&J is making to help pregnant people and their babies.

NEW DATA: Topline results for a new therapy from Janssen showed positive outcomes for pregnant adults at high risk for severe hemolytic disease of the fetus and newborn or #HDFN. Hear from Janssen’s Katie Abouzahr: bit.ly/3Yonb8U #SMFM23

Just “surviving” is how some patients describe their experiences living with warm autoimmune hemolytic anemia (#wAIHA), a rare autoantibody-driven disease. As we near #RareDiseaseDay, hear from three wAIHA warriors and their hopes for the future.

Hear from our team as they share their passion for bringing forward meaningful solutions for patients impacted by autoantibody-driven diseases, many of which are rare conditions. bit.ly/3WuqABv #RareDiseaseDay #ShowYourColors

We’re proud to invest in healthcare #DEI including support of established higher education programs that benefit individuals from historically marginalized communities. Learn how programs like these have impacted the careers of 3 #healthcare professionals: bit.ly/3KAPoFS

Meet Eileen Davidson (Eileen Davidson - Rheumatoid Arthritis Advocate) – a writer and patient advocate living with rheumatoid arthritis. RT to join us in raising awareness for the global autoimmune arthritis community this World Autoimmune & Autoinflammatory Arthritis Day. #AiArthritisDay

Those impacted by alloantibody-driven hemolytic disease of the fetus and newborn, or #HDFN, can feel isolation and deep uncertainty about what the future may hold for themselves and their babies. Learn from these courageous moms as they discuss their difficult experiences.

Only 1% of clinical trials include "pregnant" or "pregnancy" in their descriptions, contributing to the huge unmet needs in the maternal health community. Proud to be part of a team taking this on for maternal fetal conditions like #HDFN. Learn more ⬇️ #NFSAM

We’re sharing new data at #ACR23 in #RheumatoidArthritis and #PsoriaticArthritis from across our investigational and established therapies. Learn more about our latest research findings: bit.ly/3YsbwXC

Living with a rare disease can mean navigating a condition that is often under researched. We’re conducting clinical studies in idiopathic inflammatory myopathies to address patients’ unmet needs. Learn more: bit.ly/3FFUug8 #ACR23

We’re advancing the science of #ProstateCancer to improve outcomes for all patients with the disease. With our data at #ASCO25, we’re building upon our expertise in precision medicine: bit.ly/43tl6hn #JNJOncology